Shiliang Li

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 28

Top Venues

Future medicinal chemistry

Briefings in bioinformatics

Protein & cell

Journal of medicinal chemistry

East China University of Science and Technology

East China University of Science and Technology (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

East China University of Science and Technology Nov 14 2018

China

Associate professor :: School of Pharmacy

East China University of Science and Technology Jul 13 2016 - Nov 13 2018

China

PostDoc :: School of Pharmacy

Education History

East China University of Science and Technology Sep 01 2011 - Jun 15 2016

China

PHD :: School of Pharmacy

Publications

Runyu Miao, Danlin Liu, Liyun Mao, Xingyu Chen, Leihao Zhang, Zhen Yuan, Shanshan Shi, Honglin Li, Shiliang Li
GR-pKa: a message-passing neural network with retention mechanism for pKa prediction. Briefings in bioinformatics 25 (5) (2024)
Jinxin Xie, Shanshan Ruan, Mingyan Tu, Zhen Yuan, Jianguo Hu, HongLin Li, Shiliang Li
Clustering single-cell RNA sequencing data via iterative smoothing and self-supervised discriminative embedding. Oncogene 43 (29) (2024)
Zhen Yuan, Xingyu Chen, Sisi Fan, Longfeng Chang, Linna Chu, Ying Zhang, Jie Wang, Shuang Li, Jinxin Xie, Jianguo Hu, Runyu Miao, Lili Zhu, Zhenjiang Zhao, Honglin Li, Shiliang Li
Binding Free Energy Calculation Based on the Fragment Molecular Orbital Method and Its Application in Designing Novel SHP-2 Allosteric Inhibitors. International journal of molecular sciences 25 (1) (2024)
Yanyu Ma, Yidan Song, Junyi Wang, Xiayu Shi, Zhen Yuan, Shuang Li, Honglin Li, Zhuo Chen, Shiliang Li
Discovery of novel covalent inhibitors of DJ-1 through hybrid virtual screening. Future medicinal chemistry (2024)
Yanyu Ma, Yidan Song, Junyi Wang, Xiayu Shi, Zhen Yuan, Shuang Li, Honglin Li, Zhuo Chen, Shiliang Li
Discovery of novel covalent inhibitors of DJ-1 through hybrid virtual screening. Future medicinal chemistry 16 (7) (2024)
Zhen Yuan, Xingyu Chen, Sisi Fan, Longfeng Chang, Linna Chu, Ying Zhang, Jie Wang, Shuang Li, Jinxin Xie, Jianguo Hu, Runyu Miao, Lili Zhu, Zhenjiang Zhao, Honglin Li, Shiliang Li
Binding Free Energy Calculation Based on the Fragment Molecular Orbital Method and Its Application in Designing Novel SHP-2 Allosteric Inhibitors. International journal of molecular sciences 25 (1) (2024)
Jinxin Xie, Shanshan Ruan, Mingyan Tu, Zhen Yuan, Jianguo Hu, HongLin Li, Shiliang Li
Clustering single-cell RNA sequencing data via iterative smoothing and self-supervised discriminative embedding. Oncogene (2024)
Yanyu Ma, Yidan Song, Junyi Wang, Xiayu Shi, Zhen Yuan, Shuang Li, Honglin Li, Zhuo Chen, Shiliang Li
Discovery of novel covalent inhibitors of DJ-1 through hybrid virtual screening. Future medicinal chemistry 16 (7) (2024)
Zhen Yuan, Xingyu Chen, Sisi Fan, Longfeng Chang, Linna Chu, Ying Zhang, Jie Wang, Shuang Li, Jinxin Xie, Jianguo Hu, Runyu Miao, Lili Zhu, Zhenjiang Zhao, Honglin Li, Shiliang Li
Binding Free Energy Calculation Based on the Fragment Molecular Orbital Method and Its Application in Designing Novel SHP-2 Allosteric Inhibitors. International journal of molecular sciences 25 (1) (2024)
Runyu Miao, Danlin Liu, Liyun Mao, Xingyu Chen, Leihao Zhang, Zhen Yuan, Shanshan Shi, Honglin Li, Shiliang Li
GR-pKa: a message-passing neural network with retention mechanism for pKa prediction. Briefings in bioinformatics 25 (5) (2024)
Yanyu Ma, Yidan Song, Junyi Wang, Xiayu Shi, Zhen Yuan, Shuang Li, Honglin Li, Zhuo Chen, Shiliang Li
Discovery of novel covalent inhibitors of DJ-1 through hybrid virtual screening. Future medicinal chemistry 16 (7) (2024)
Yanyu Ma, Yidan Song, Junyi Wang, Xiayu Shi, Zhen Yuan, Shuang Li, Honglin Li, Zhuo Chen, Shiliang Li
Discovery of novel covalent inhibitors of DJ-1 through hybrid virtual screening. Future medicinal chemistry 16 (7) (2024)
Fang Bai, Shiliang Li, Honglin Li
AI enhances drug discovery and development. National science review 11 (3) (2023)
Thian-Sze Wong, Guangzhi Li, Shiliang Li, Wei Gao, Geng Chen, Shiyi Gan, Manzhan Zhang, HongLin Li, Song Wu, Yang Du
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. Signal transduction and targeted therapy 8 (1) (2023)
Thian-Sze Wong, Guangzhi Li, Shiliang Li, Wei Gao, Geng Chen, Shiyi Gan, Manzhan Zhang, HongLin Li, Song Wu, Yang Du
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. Signal transduction and targeted therapy 8 (1) (2023)
Fang Bai, Shiliang Li, Honglin Li
AI enhances drug discovery and development. National science review 11 (3) (2023)
Thian-Sze Wong, Guangzhi Li, Shiliang Li, Wei Gao, Geng Chen, Shiyi Gan, Manzhan Zhang, HongLin Li, Song Wu, Yang Du
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. Signal transduction and targeted therapy 8 (1) (2023)
Jie Wang, Zihao Shen, Yichen Liao, Zhen Yuan, Shiliang Li, Gaoqi He, Man Lan, Xuhong Qian, Kai Zhang, Honglin Li
Multi-modal chemical information reconstruction from images and texts for exploring the near-drug space. Briefings in bioinformatics 23 (6) (2022)
Yucheng Zheng, Shiliang Li, Kun Song, Jiajie Ye, Wenkang Li, Yifan Zhong, Ziyan Feng, Simeng Liang, Zeng Cai, Ke Xu
A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses. Viruses 14 (5) (2022)
Ziyan Feng, Zihao Shen, Honglin Li, Shiliang Li
e-TSN: an interactive visual exploration platform for target-disease knowledge mapping from literature. Briefings in bioinformatics 23 (6) (2022)
Mengdie Gong, Mingyan Tu, Hongxia Sun, Lu Li, Lili Zhu, Honglin Li, Zhenjiang Zhao, Shiliang Li
Design, Synthesis, and Structure-Activity Relationship Study of Potent MAPK11 Inhibitors. Molecules (Basel, Switzerland) 27 (1) (2021)
Yuan Yuan, Junpeng Xu, Lei Jiang, Kangjie Yu, Yuanyuan Ge, Mingyang Li, Huan He, Qiqi Niu, Xiayu Shi, Linni Fan, Zhuo Chen, Zhenjiang Zhao, Shiliang Li, Yufang Xu, Zhe Wang, HongLin Li
Discovery, Optimization, and Structure-Activity Relationship Study of Novel and Potent RSK4 Inhibitors as Promising Agents for the Treatment of Esophageal Squamous Cell Carcinoma. Journal of medicinal chemistry 64 (18) (2021)
Shiliang Li, Chaoqian Cai, Jiayu Gong, Xiaofeng Liu, HongLin Li
A fast protein binding site comparison algorithm for proteome-wide protein function prediction and drug repurposing. Proteins 89 (11) (2021)
Rui Xiong, Leike Zhang, Shiliang Li, Yuan Sun, Minyi Ding, Yong Wang, Yongliang Zhao, Yan Wu, Weijuan Shang, Xiaming Jiang, Jiwei Shan, Zihao Shen, Yi Tong, Liuxin Xu, Yu Chen, Yingle Liu, Gang Zou, Dimitri Lavillete, Zhenjiang Zhao, Rui Wang, Lili Zhu, Gengfu Xiao, Ke Lan, HongLin Li, Ke Xu
Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein & cell (2020)
Rui Xiong, Leike Zhang, Shiliang Li, Yuan Sun, Minyi Ding, Yong Wang, Yongliang Zhao, Yan Wu, Weijuan Shang, Xiaming Jiang, Jiwei Shan, Zihao Shen, Yi Tong, Liuxin Xu, Yu Chen, Yingle Liu, Gang Zou, Dimitri Lavillette, Zhenjiang Zhao, Rui Wang, Lili Zhu, Gengfu Xiao, Ke Lan, HongLin Li, Ke Xu
Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein & cell (2020)
Rui Xiong, Leike Zhang, Shiliang Li, Yuan Sun, Minyi Ding, Yong Wang, Yongliang Zhao, Yan Wu, Weijuan Shang, Xiaming Jiang, Jiwei Shan, Zihao Shen, Yi Tong, Liuxin Xu, Yu Chen, Yingle Liu, Gang Zou, Dimitri Lavillete, Zhenjiang Zhao, Rui Wang, Lili Zhu, Gengfu Xiao, Ke Lan, HongLin Li, Ke Xu
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein & cell 11 (10) (2020)
Shiliang Li, Chun Qin, Shichao Cui, Hongling Xu, Fangshu Wu, Jiawei Wang, Mingbo Su, Xiaoyu Fang, Dan Li, Qian Jiao, Ming Zhang, Chunmei Xia, Lili Zhu, Rui Wang, Jia Li, Hualiang Jiang, Zhenjiang Zhao, Jingya Li, HongLin Li
Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes. Journal of medicinal chemistry 62 (5) (2019)
Shiliang Li, Chun Qin, Shichao Cui, Hongling Xu, Fangshu Wu, Jiawei Wang, Mingbo Su, Xiaoyu Fang, Dan Li, Qian Jiao, Ming Zhang, Chunmei Xia, Lili Zhu, Rui Wang, Jia Li, Hualiang Jiang, Zhenjiang Zhao, Jingya Li, HongLin Li
Correction to Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes. Journal of medicinal chemistry 62 (9) (2019)

Shiliang Li.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Shiliang Li